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Severe cases (grade 3-4) are more challenging and often fail medical intervention requiring a more aggressive/invasive approach. This may include bladder washouts, endoscope examination with cauterization of bleeding mucosa and, in some cases, instillation of formalin or pressure balloon that may carry the risk of future bladder retraction and incontinence. Keratinocyte growth factor (KGF) is a growth factor that promotes proliferation of various epithelial cells. Its proliferative capability on urothelium was described in vivo by Yi et al. 2 Ulich et al. illustrated that KGF was effective in attenuating cyclophosphamide-induced HC utilizing a murine model. Furthermore, this study provided evidence that bilateral nephrectomy and the absence of urinary KGF did not abolish its protective effect. 3 To date, the only published data of KGF use in humans is that of a 24-year-old man with severe, lateonset refractory HC post allogeneic HCT for refractory T-acute lymphoblastic leukemia. Bleeding stopped after 12 doses of KGF; however, it reappeared shortly after discontinuation of the treatment, but again resolved after additional doses of KGF. 4 We report the first case of a pediatric patient with severe refractory grade 4 HC who responded to KGF after failing several first-and second-line therapies.
CASE REPORT
A 12-year-old female underwent a 10/10 HLA allelic-matched unrelated BMT to treat relapse AML using myeloablative conditioning with i.v. BU, CY and rabbit antithymocyte globulin; GVHD prophylaxis included tacrolimus and short-course methotrexate.
Her immediate post-transplant toxicity included severe mucositis and anuric acute kidney injury with fluid overload and hypotensive shock. On day +4, she received continuous venovenous hemodialysis (CVVHD) and was subsequently transitioned to intermittent hemodialysis. Concurrently she had moderate sinusoidal obstructive syndrome of the liver and was treated with defibrotide for 9 days from day +15 to day +23 with excellent response.
On day +22 post transplant, the patient developed acute dysuria, urgency and gross hematuria with large clots. Quantitative urine BK PCR was positive with more than 5 000 000 copies/mL BK viruria; however, plasma BK-virus PCR studies were negative. Platelet count ranged from 20 to 50 × 10 9 /L throughout her course but was transfused frequently in an attempt to keep her platelet count above 75 × 10 9 /L. Irrigation of the bladder using a catheter was attempted several times but was unsuccessful. On day +36, she underwent a cystoscopy with clot evacuation, open placement of a suprapubic catheter and instillation of intra-vesicular cidofovir. She received 2 doses of intra-vesicular cidofovir (5 mg/kg in 60 mL normal saline (NS) indwelling for 1 h) followed by the initiation of continuous bladder irrigation. A bladder biopsy on day +36 showed a lesion with necrotic debris and multiple pseudohyphae and budding yeast consistent with Candida krusei. In addition to systemic antifungal therapy she received 7 daily amphotericin bladder washes starting on day +62. Owing to worsening symptoms the patient received a second course of intravesicular cidofivir on days +50 and 51, and prostaglandin E2 (750 mcg in 100 ml NS indwell for 60 min) on days +58, 61 and 62.
On day +77, she underwent repeat cystoscopy with fulguration. Fungal culture and stains were negative at that time. The patient was maintained on continuous bladder irrigation via the suprapubic catheter for 60 days; by day +96, due to patient's discomfort and improvement in renal function the catheter was removed. The gross severe hematuria and BK viruria, however, persisted; weekly low-dose i.v. cidofivir at 1 mg/kg/dose was started on days +130 to +158 followed by the initiation of hyperbaric oxygen therapy on day +147. Despite 17 days of such therapy, gross hematuria persisted and on day +164 i.v. KGF was initiated at a dose of 60 mcg/kg/dose daily for 3 days/week. Although hyperbaric oxygen was continued, 1 week after the initiation of KGF, for the first time, the patient had a decrease in clot passage. Her symptoms continued to improve with complete resolution of gross hematuria 2 weeks after initiation of KGF therapy (day +180). She received a total of 4 weeks of KGF. Urinary BK level prior to KGF was 3300 copies/mL and decreased to 2000 copies/mL 1 week after the initiation of KGF. Levels were not monitored thereafter due to the resolution of symptoms. Figure 1 illustrates that the red cell transfusion requirement did not change until after the initiation of KGF. Although the patient's need for red cell transfusion completely resolved with the resolution of hematuria, platelet count continued to be in the 30 × 10 9 /L range. She was diagnosed with poor graft function and received a CD34-selected stem cell boost on day 220 post transplant that led to a normal platelet count thereafter. The patient had no recurrence of symptoms after discontinuation of KGF therapy and she remains in CR now 1 year post transplant.
Although unlikely, we cannot rule out that the longer duration of hyperbaric oxygen therapy may have contributed to the final resolution of HC. However, timing of the symptom resolution suggests that it may be an important component either alone or in a combined modality approach. Our findings suggest that KGF could be an option for the treatment of BK-induced grade 4 HC post HCT. Although the total drug cost of this therapy for our patient was estimated at 18 150 USD, the ease of administration, convenient dosing schedule and safety side-effect profile of KGF makes it superior to other therapeutic options. Whether early 
